Literature DB >> 26898256

Author`s Reply.

Hakan Uçar1, Mustafa Gür2, Murat Çaylı3.   

Abstract

Entities:  

Year:  2016        PMID: 26898256      PMCID: PMC5336733     

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We thank the authors for their great interest in our work entitled “Relationship between extent and complexity of coronary artery disease and different left ventricular geometric patterns in patients with coronary artery disease and hypertension” that was published in the October 2015; 15: 789-794 issue of the Anatol J Cardiol (1). As reported, we found that the SYNTAX score is independently related with the LV geometry in patients with hypertension. Moreover, this result demonstrates that LV remodeling is parallel to the increase in the extent and complexity of CAD in our study patients (1). We discussed several mechanisms to explain the study results. We mentioned that in particular, the renin–angiotensin–aldosterone system can be the most important mechanism. Angiotensin II and angiotensin II type 1 receptor activation promote intracellular reactions that may lead to both cardiac hypertrophy and the progression of complex atherosclerotic lesions through the proliferation of vascular smooth muscle cells and the production of extracellular matrix protein (2). Furthermore, we discussed that oxidative stress contributes to the progression of atherosclerosis in patients with hypertension having different LV geometries (3). As mentioned in the letter, IR and proinflammatory state have been reported to be associated with the LV growth and CAD in patients with hypertension (4, 5). However, we did not measure IR and any inflammatory marker. Furthermore, although we examined the hospital data, we did not find any values for these parameters. Measuring IR and inflammatory marker levels could provide insights into the pathogenesis of different LV geometries and its relationship with CAD severity in patients with hypertension. Further studies can be designed to determine the effects of IR and inflammatory markers for these patients.
  5 in total

1.  Effect of insulin resistance on left ventricular structural changes in hypertensive patients.

Authors:  H Asuman Kaftan; Harun Evrengul; Halil Tanriverdi; Mustafa Kilic
Journal:  Int Heart J       Date:  2006-05       Impact factor: 1.862

Review 2.  Tissue renin-angiotensin system in myocardial hypertrophy and failure.

Authors:  V J Dzau
Journal:  Arch Intern Med       Date:  1993-04-26

3.  Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy.

Authors:  Elen Rizzi; Carla S Ceron; Danielle A Guimaraes; Cibele M Prado; Marcos A Rossi; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Exp Mol Pathol       Date:  2012-10-13       Impact factor: 3.362

Review 4.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Authors:  Stephane Heymans; Emilio Hirsch; Stefan D Anker; Pal Aukrust; Jean-Luc Balligand; Jan W Cohen-Tervaert; Helmut Drexler; Gerasimos Filippatos; Stephan B Felix; Lars Gullestad; Denise Hilfiker-Kleiner; Stefan Janssens; Roberto Latini; Gitte Neubauer; Walter J Paulus; Burkert Pieske; Piotr Ponikowski; Blanche Schroen; Heinz-Peter Schultheiss; Carsten Tschöpe; Marc Van Bilsen; Faiez Zannad; John McMurray; Ajay M Shah
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

5.  Relationship between extent and complexity of coronary artery disease and different left ventricular geometric patterns in patients with coronary artery disease and hypertension.

Authors:  Hakan Uçar; Mustafa Gür; Abdürrezzak Börekçi; Arafat Yıldırım; Ahmet Oytun Baykan; Gülhan Yüksel Kalkan; Mevlüt Koç; Taner Şeker; Mehmet Coşkun; Ömer Şen; Murat Çaylı
Journal:  Anatol J Cardiol       Date:  2014-10-15       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.